Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

The equity awards require continued employee service to vest, with options priced at the grant-date closing share price.

Rhea-AI Summary

Edgewise Therapeutics (EWTX) granted inducement stock options and restricted stock units to three new non-executive employees on September 30, 2026. The options cover 7,500 shares at an exercise price of $40.60 per share, equal to the grant-date closing price. Restricted stock units cover 3,751 shares.

The awards were granted under the 2024 Inducement Equity Incentive Plan. Options vest 25% on each employee's first start-date anniversary, then 1/48th monthly. Restricted stock units vest one-fourth on each of the first four grant-date anniversaries. Both schedules require continued service. The grants comply with Nasdaq Listing Rule 5635(c)(4).

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.7,500 inducement stock options at $40.60 per share create potential dilution as they vest and are exercised.
• Minor point. Forward-looking: it has not happened yet and may not happen.3,751 restricted stock units create potential dilution as they vest, subject to continued employee service.

Key Figures

Option awards: 7,500 shares RSU awards: 3,751 shares Employees receiving awards: 3 employees +3 more

Option awards

7,500 shares

Inducement stock options granted to new employees

RSU awards

3,751 shares

Inducement restricted stock units granted to new employees

Employees receiving awards

3 employees

New non-executive employees

Option exercise price

$40.60 per share

Equal to the closing share price on the grant date

Option vesting

25% after 1 year, then 1/48 monthly

Subject to continued employee service

RSU vesting

1/4 annually over 4 years

Subject to continued employee service

Key Terms

restricted stock units

1 terms

restricted stock units financial

"awards of inducement restricted stock units (each, an "RSU award")"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOULDER, Colo., Oct. 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that on September 30, 2026, Edgewise granted inducement stock options to purchase a total of 7,500 shares of Edgewise's common stock and awards of inducement restricted stock units (each, an "RSU award") covering a total of 3,751 shares of Edgewise's common stock to 3 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan"). 

Each inducement stock option has an exercise price of $40.60 per share, which is equal to the closing price of a share of Edgewise common stock on the grant date, and shall vest as follows: 25% of the shares subject to such inducement stock option shall vest on the one year anniversary of the start date of each employee, and an additional one forty-eighth (1/48th) of the shares subject to such inducement stock option shall vest monthly thereafter, subject to the employee's continued service.

Each inducement RSU award shall vest as follows: one-fourth (1/4th) of the shares subject to each inducement RSU award shall vest on the first, second, third and fourth yearly anniversaries of the grant date, subject to the employee's continued service.

Each inducement award is subject to the terms of the Inducement Plan and related forms of agreements, and were granted as inducements material to these employees to enter into employment with Edgewise in accordance with Nasdaq Listing Rule 5635(c)(4). 

About Edgewise Therapeutics

Edgewise Therapeutics is a cardiometabolic biotechnology company pioneering a new field of medicine centered on restoring cardiac equilibrium—the dynamic balance of the cardiac cycle. Drawing on deep expertise in integrated muscle physiology and small molecule drug development, Edgewise is advancing first-in-class therapies designed to fine-tune cardiac muscle function and redefine the treatment of symptomatic hypertrophic cardiomyopathy and heart failure. To learn more, go to edgewisetx.com or follow Edgewise on LinkedIn, X, Facebook and Instagram.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-302895364.html

SOURCE Edgewise Therapeutics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement equity awards did Edgewise Therapeutics grant on September 30, 2026?

Edgewise granted three new non-executive employees options covering 7,500 shares and restricted stock units covering 3,751 shares. The options have an exercise price of $40.60 per share, equal to the closing share price on the grant date.

When do Edgewise Therapeutics' September 30, 2026 inducement awards vest?

The options vest 25% on each employee's first start-date anniversary, followed by 1/48th monthly thereafter. Restricted stock units vest one-fourth on each of the first, second, third and fourth anniversaries of the grant date. Both schedules are subject to continued employee service.